首页 > 最新文献

European Heart Journal Supplements最新文献

英文 中文
Over 10 years of non-vitamin K antagonist oral anticoagulants: highlights, challenges, and future developments.
IF 1.7 4区 医学 Q3 CARDIAC & CARDIOVASCULAR SYSTEMS Pub Date : 2025-02-19 eCollection Date: 2025-02-01 DOI: 10.1093/eurheartjsupp/suae087
Raffaele De Caterina, Simona Chiusolo

Over the past decade, non-vitamin K antagonist oral anticoagulants have revolutionized anticoagulation therapy, offering substantial benefits over traditional vitamin K antagonists. Non-vitamin K antagonist oral anticoagulants offer reduced bleeding risks, fixed dosing without frequent monitoring, and fewer drug and dietary interactions. Their effectiveness has been demonstrated in preventing stroke in atrial fibrillation, managing venous thromboembolism, and offering new options for patients with coronary artery disease and cancer-associated thrombosis. However, challenges remain, including bleeding risks, high costs, and limited efficacy in certain patient populations. Current research is focused on addressing these limitations, with Factor XI inhibitors emerging as a promising advancement for safer anticoagulation. This review provides an overview of the clinical highlights, challenges, and future directions of anticoagulation therapy.

{"title":"Over 10 years of non-vitamin K antagonist oral anticoagulants: highlights, challenges, and future developments.","authors":"Raffaele De Caterina, Simona Chiusolo","doi":"10.1093/eurheartjsupp/suae087","DOIUrl":"10.1093/eurheartjsupp/suae087","url":null,"abstract":"<p><p>Over the past decade, non-vitamin K antagonist oral anticoagulants have revolutionized anticoagulation therapy, offering substantial benefits over traditional vitamin K antagonists. Non-vitamin K antagonist oral anticoagulants offer reduced bleeding risks, fixed dosing without frequent monitoring, and fewer drug and dietary interactions. Their effectiveness has been demonstrated in preventing stroke in atrial fibrillation, managing venous thromboembolism, and offering new options for patients with coronary artery disease and cancer-associated thrombosis. However, challenges remain, including bleeding risks, high costs, and limited efficacy in certain patient populations. Current research is focused on addressing these limitations, with Factor XI inhibitors emerging as a promising advancement for safer anticoagulation. This review provides an overview of the clinical highlights, challenges, and future directions of anticoagulation therapy.</p>","PeriodicalId":11956,"journal":{"name":"European Heart Journal Supplements","volume":"27 Suppl 1","pages":"i6-i11"},"PeriodicalIF":1.7,"publicationDate":"2025-02-19","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11836674/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143467109","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Pacing of the specialized His Purkinje conduction system: 'HOW and FOR WHOM'.
IF 1.7 4区 医学 Q3 CARDIAC & CARDIOVASCULAR SYSTEMS Pub Date : 2025-02-19 eCollection Date: 2025-02-01 DOI: 10.1093/eurheartjsupp/suae113
Emanuele Chiarazzo, Paolo Golia, Edoardo Bressi, Domenico Grieco, Ermenegildo De Ruvo, Leonardo Calò

The human heart's conduction system consists of specialized cardiomyocytes that generate and transmit electrical impulses, leading to the rhythmic and synchronized contraction of the atria and ventricles, which is crucial for the normal cardiac cycle. In conduction system pacing (CSP), pacing leads are placed in the His bundle region and the left bundle branch area to achieve physiological cardiac activation. This method offers a more natural alternative to the myocardial stimulation provided by conventional right ventricular pacing and biventricular pacing. In this review, we describe the implantation techniques for CSP and discuss the current recommendations for their use.

{"title":"Pacing of the specialized His Purkinje conduction system: 'HOW and FOR WHOM'.","authors":"Emanuele Chiarazzo, Paolo Golia, Edoardo Bressi, Domenico Grieco, Ermenegildo De Ruvo, Leonardo Calò","doi":"10.1093/eurheartjsupp/suae113","DOIUrl":"10.1093/eurheartjsupp/suae113","url":null,"abstract":"<p><p>The human heart's conduction system consists of specialized cardiomyocytes that generate and transmit electrical impulses, leading to the rhythmic and synchronized contraction of the atria and ventricles, which is crucial for the normal cardiac cycle. In conduction system pacing (CSP), pacing leads are placed in the His bundle region and the left bundle branch area to achieve physiological cardiac activation. This method offers a more natural alternative to the myocardial stimulation provided by conventional right ventricular pacing and biventricular pacing. In this review, we describe the implantation techniques for CSP and discuss the current recommendations for their use.</p>","PeriodicalId":11956,"journal":{"name":"European Heart Journal Supplements","volume":"27 Suppl 1","pages":"i141-i148"},"PeriodicalIF":1.7,"publicationDate":"2025-02-19","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11836725/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143467139","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
The role of antiarrhythmic drugs and stellate ganglion block in the acute management of electrical storm.
IF 1.7 4区 医学 Q3 CARDIAC & CARDIOVASCULAR SYSTEMS Pub Date : 2025-02-19 eCollection Date: 2025-02-01 DOI: 10.1093/eurheartjsupp/suae084
Veronica Dusi, Filippo Angelini, Carol Gravinese, Simone Frea, Gaetano Maria De Ferrari

Electrical storm (ES) is a life-threatening condition characterized by at least three separate episodes of ventricular arrhythmia (VAs) over 24 h, each one requiring intervention. Early recognition and prompt treatment are crucial to improving outcomes. In addition to identifying and correcting potential reversible causes, performing acute cardiac life support if required, and interrogating/reprogramming the implantable cardioverter defibrillator in present, the acute management of ES (within 12-24 h upon presentation) nowadays mostly relies on antiarrhythmic drugs and percutaneous left ganglion sympathetic block (PLSGB), that will be the focus of the present review. The choice of the drug should consider several factors, including the aetiology and mechanism of VAs, the underlying cardiac function, and the potential risk of adverse events. Intravenous amiodarone, the most used and recommended drug in the setting of high burden VAs and structural heart disorders, mostly exerts dose and rate infusion dependent antiadrenergic effects in the first hours, and may lead to severe hypotension. PLSGB has an excellent safety-efficacy profile and can be easily performed by trained cardiologists at bedside.

电风暴(ES)是一种危及生命的疾病,其特征是在 24 小时内至少有三次独立的室性心律失常(VAs)发作,每次发作都需要干预。早期识别和及时治疗对改善预后至关重要。除了识别和纠正潜在的可逆性病因、必要时实施急性心脏生命支持以及对植入式心律转复除颤器进行询问/重新编程外,目前 ES 的急性治疗(发病后 12-24 小时内)大多依赖于抗心律失常药物和经皮左侧神经节交感神经阻滞(PLSGB),这将是本综述的重点。药物的选择应考虑多个因素,包括 VAs 的病因和机制、基础心脏功能以及不良事件的潜在风险。静脉注射胺碘酮是高负担 VAs 和结构性心脏疾病情况下最常用和最推荐的药物,其抗肾上腺素能作用大多在最初几小时内发挥,且依赖于剂量和输注速度,并可能导致严重低血压。PLSGB 具有极佳的安全性和有效性,训练有素的心脏病专家可在床旁轻松实施。
{"title":"The role of antiarrhythmic drugs and stellate ganglion block in the acute management of electrical storm.","authors":"Veronica Dusi, Filippo Angelini, Carol Gravinese, Simone Frea, Gaetano Maria De Ferrari","doi":"10.1093/eurheartjsupp/suae084","DOIUrl":"10.1093/eurheartjsupp/suae084","url":null,"abstract":"<p><p>Electrical storm (ES) is a life-threatening condition characterized by at least three separate episodes of ventricular arrhythmia (VAs) over 24 h, each one requiring intervention. Early recognition and prompt treatment are crucial to improving outcomes. In addition to identifying and correcting potential reversible causes, performing acute cardiac life support if required, and interrogating/reprogramming the implantable cardioverter defibrillator in present, the acute management of ES (within 12-24 h upon presentation) nowadays mostly relies on antiarrhythmic drugs and percutaneous left ganglion sympathetic block (PLSGB), that will be the focus of the present review. The choice of the drug should consider several factors, including the aetiology and mechanism of VAs, the underlying cardiac function, and the potential risk of adverse events. Intravenous amiodarone, the most used and recommended drug in the setting of high burden VAs and structural heart disorders, mostly exerts dose and rate infusion dependent antiadrenergic effects in the first hours, and may lead to severe hypotension. PLSGB has an excellent safety-efficacy profile and can be easily performed by trained cardiologists at bedside.</p>","PeriodicalId":11956,"journal":{"name":"European Heart Journal Supplements","volume":"27 Suppl 1","pages":"i154-i161"},"PeriodicalIF":1.7,"publicationDate":"2025-02-19","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11836683/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143467279","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Cardiac amyloidosis: Innovations in diagnosis and treatment.
IF 1.7 4区 医学 Q3 CARDIAC & CARDIOVASCULAR SYSTEMS Pub Date : 2025-02-19 eCollection Date: 2025-02-01 DOI: 10.1093/eurheartjsupp/suae111
Vincenzo Castiglione, Sabrina Montuoro, Giulia Orlando, Alberto Aimo, Giuseppe Vergaro, Michele Emdin

Cardiac amyloidosis (CA) is a progressive, underdiagnosed condition caused by the deposition of misfolded proteins in the myocardium, forming amyloid fibrils that impair cardiac structure and function. This review highlights recent advances in the diagnosis and treatment of amyloid light-chain (AL) and transthyretin (ATTR) CA, which globally account for most cases of CA. Novel diagnostic tools, including artificial intelligence-enhanced analysis and advanced imaging modalities like positron emission tomography with amyloid-specific tracers, might improve detection rates and diagnostic accuracy to enable non-invasive subtype differentiation. Furthermore, many innovative treatments are being investigated. For AL-CA, anti-fibril therapies are showing promising results, complementing traditional chemotherapy and autologous stem cell transplantation. In ATTR-CA, gene silencing and anti-fibril therapies are being tested in clinical trials and hold promise of halting disease progression and reducing amyloid deposits, respectively.

{"title":"Cardiac amyloidosis: Innovations in diagnosis and treatment.","authors":"Vincenzo Castiglione, Sabrina Montuoro, Giulia Orlando, Alberto Aimo, Giuseppe Vergaro, Michele Emdin","doi":"10.1093/eurheartjsupp/suae111","DOIUrl":"10.1093/eurheartjsupp/suae111","url":null,"abstract":"<p><p>Cardiac amyloidosis (CA) is a progressive, underdiagnosed condition caused by the deposition of misfolded proteins in the myocardium, forming amyloid fibrils that impair cardiac structure and function. This review highlights recent advances in the diagnosis and treatment of amyloid light-chain (AL) and transthyretin (ATTR) CA, which globally account for most cases of CA. Novel diagnostic tools, including artificial intelligence-enhanced analysis and advanced imaging modalities like positron emission tomography with amyloid-specific tracers, might improve detection rates and diagnostic accuracy to enable non-invasive subtype differentiation. Furthermore, many innovative treatments are being investigated. For AL-CA, anti-fibril therapies are showing promising results, complementing traditional chemotherapy and autologous stem cell transplantation. In ATTR-CA, gene silencing and anti-fibril therapies are being tested in clinical trials and hold promise of halting disease progression and reducing amyloid deposits, respectively.</p>","PeriodicalId":11956,"journal":{"name":"European Heart Journal Supplements","volume":"27 Suppl 1","pages":"i88-i97"},"PeriodicalIF":1.7,"publicationDate":"2025-02-19","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11836727/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143467355","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Towards a phenotype profiling of the patients with heart failure and preserved ejection fraction.
IF 1.7 4区 医学 Q3 CARDIAC & CARDIOVASCULAR SYSTEMS Pub Date : 2025-02-19 eCollection Date: 2025-02-01 DOI: 10.1093/eurheartjsupp/suae095
Giovanni Battista Bonfioli, Matteo Pagnesi, Leonardo Calò, Marco Metra

The prevalence of heart failure with preserved ejection fraction (HFpEF) is increasing and prognosis remains poor, with a high risk of mortality or hospitalizations for worsening heart failure events. Apart from sodium-glucose cotransporter-2 inhibitors and diuretics, the management of HFpEF is nowadays based on the different aetiologies and cardiovascular or non-cardiovascular comorbidities. A great heterogeneity of clinical profiles has been described in HFpEF, with several recent studies focused on the identification of different HFpEF phenotypes. In this review, we summarize available evidence on phenotype profiling in HFpEF, describing the different phenotypes with the relative therapeutic implications, and reporting other specific clinical conditions relevant for HFpEF differential diagnosis.

{"title":"Towards a phenotype profiling of the patients with heart failure and preserved ejection fraction.","authors":"Giovanni Battista Bonfioli, Matteo Pagnesi, Leonardo Calò, Marco Metra","doi":"10.1093/eurheartjsupp/suae095","DOIUrl":"10.1093/eurheartjsupp/suae095","url":null,"abstract":"<p><p>The prevalence of heart failure with preserved ejection fraction (HFpEF) is increasing and prognosis remains poor, with a high risk of mortality or hospitalizations for worsening heart failure events. Apart from sodium-glucose cotransporter-2 inhibitors and diuretics, the management of HFpEF is nowadays based on the different aetiologies and cardiovascular or non-cardiovascular comorbidities. A great heterogeneity of clinical profiles has been described in HFpEF, with several recent studies focused on the identification of different HFpEF phenotypes. In this review, we summarize available evidence on phenotype profiling in HFpEF, describing the different phenotypes with the relative therapeutic implications, and reporting other specific clinical conditions relevant for HFpEF differential diagnosis.</p>","PeriodicalId":11956,"journal":{"name":"European Heart Journal Supplements","volume":"27 Suppl 1","pages":"i115-i121"},"PeriodicalIF":1.7,"publicationDate":"2025-02-19","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11836726/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143467427","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Can we slow down the decline in renal function?
IF 1.7 4区 医学 Q3 CARDIAC & CARDIOVASCULAR SYSTEMS Pub Date : 2025-02-19 eCollection Date: 2025-02-01 DOI: 10.1093/eurheartjsupp/suae123
Gennaro Cice, Leonardo Calò

The 'chronic kidney disease' (CKD) definition that best outlines the complex syndrome commonly called 'kidney failure' has become a problem of World Public Health due to its incidence and prevalence and due to exponentially increasing costs in every part of the world. The progressive reduction in the glomerular filtration rate, as known, goes hand in hand with an increase in cardiovascular risk understood as fatal and non-fatal heart attack, stroke, heart failure, and mortality. Therefore, every effort must aim at preventing or slowing down the decline in renal function in order to reduce not only critical renal events (the need for dialysis or transplantation among the most dreadful) but also the incidence of cardiovascular events. Since the disease is asymptomatic for a long time (often its detection is occasional and done with guilty delay), it is clearly important to make a correct and early evaluation of renal function with appropriate methods. Furthermore, it is crucial to make an aetiological diagnosis, when it is possible, of CKD because this will allow for the most targeted therapy possible. For a long time, an effective approach for the majority of people with CKD could only count on strict control of the diabetic disease and its complications, optimization of high blood pressure values, and the mandatory use of drugs blocking the renin-angiotensin-aldosterone system, particularly in the presence of albuminuria. Over time, this strategy proved to be only partially effective and the majority of patients nonetheless showed a progressive worsening of renal function. Only recently have we had access to two classes of innovative drugs such as glyphozines and incretins which have established themselves on the therapeutic scene because they have shown to be able to slow down the progression of CKD, first in patients with type 2 diabetes and subsequently in patients with CKD whether or not they have diabetes. Unexpectedly and convincingly, they have also been shown to significantly impact cardiovascular prognosis. From initially antidiabetic drugs, their effectiveness has forced the medical iconography to enrich itself with a new therapeutic niche by rightly speaking of 'cardio-nephro-metabolic' drugs.

{"title":"Can we slow down the decline in renal function?","authors":"Gennaro Cice, Leonardo Calò","doi":"10.1093/eurheartjsupp/suae123","DOIUrl":"10.1093/eurheartjsupp/suae123","url":null,"abstract":"<p><p>The 'chronic kidney disease' (CKD) definition that best outlines the complex syndrome commonly called 'kidney failure' has become a problem of World Public Health due to its incidence and prevalence and due to exponentially increasing costs in every part of the world. The progressive reduction in the glomerular filtration rate, as known, goes hand in hand with an increase in cardiovascular risk understood as fatal and non-fatal heart attack, stroke, heart failure, and mortality. Therefore, every effort must aim at preventing or slowing down the decline in renal function in order to reduce not only critical renal events (the need for dialysis or transplantation among the most dreadful) but also the incidence of cardiovascular events. Since the disease is asymptomatic for a long time (often its detection is occasional and done with guilty delay), it is clearly important to make a correct and early evaluation of renal function with appropriate methods. Furthermore, it is crucial to make an aetiological diagnosis, when it is possible, of CKD because this will allow for the most targeted therapy possible. For a long time, an effective approach for the majority of people with CKD could only count on strict control of the diabetic disease and its complications, optimization of high blood pressure values, and the mandatory use of drugs blocking the renin-angiotensin-aldosterone system, particularly in the presence of albuminuria. Over time, this strategy proved to be only partially effective and the majority of patients nonetheless showed a progressive worsening of renal function. Only recently have we had access to two classes of innovative drugs such as glyphozines and incretins which have established themselves on the therapeutic scene because they have shown to be able to slow down the progression of CKD, first in patients with type 2 diabetes and subsequently in patients with CKD whether or not they have diabetes. Unexpectedly and convincingly, they have also been shown to significantly impact cardiovascular prognosis. From initially antidiabetic drugs, their effectiveness has forced the medical iconography to enrich itself with a new therapeutic niche by rightly speaking of 'cardio-nephro-metabolic' drugs.</p>","PeriodicalId":11956,"journal":{"name":"European Heart Journal Supplements","volume":"27 Suppl 1","pages":"i149-i153"},"PeriodicalIF":1.7,"publicationDate":"2025-02-19","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11836728/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143467354","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Managing long QT syndrome patients, cooking, and common sense.
IF 1.7 4区 医学 Q3 CARDIAC & CARDIOVASCULAR SYSTEMS Pub Date : 2025-02-19 eCollection Date: 2025-02-01 DOI: 10.1093/eurheartjsupp/suae085
Peter J Schwartz, Federica Dagradi, Fulvio L F Giovenzana, Paolo Cerea

This essay stems from a controversial recommendation present in the 2022 European Guidelines which indicated the appropriateness of considering an implantable cardioverter defibrillator (ICD) implant even for still asymptomatic long QT syndrome (LQTS) patients deemed to be at high risk by the 1-2-3 LQTS score based on QTc and genotype calculated prior to the institution of therapy. As 15 years ago, we also had proposed, but never used, a risk score called M-FACT to identify patients at high risk of an appropriate ICD shock, we felt the responsibility of assessing what would have happened to our patients if we had rigorously used that score. We performed a study recently published in the European Heart Journal which brought to general attention two concepts important for clinical management. One is that all LQTS patients should be seen at least once a year for a reassessment of arrhythmic risk based on standard electrocardiogram, 12-lead 24 h Holter recording and an exercise stress test. The other is that, based on these yearly visits, we perform 'therapy optimization' by adding to the standard β-blocker therapy either left cardiac sympathetic denervation or mexiletine or an ICD implant. On almost 1000 LQTS patients, all genotyped, this dynamic approach was accompanied by not a single death, few events, and out of 142 patients who should have received an ICD based on the score, only 22 did and only 3 had an ICD shock. These data and concepts call for a reconsideration of the recommendation made by the guidelines.

{"title":"Managing long QT syndrome patients, cooking, and common sense.","authors":"Peter J Schwartz, Federica Dagradi, Fulvio L F Giovenzana, Paolo Cerea","doi":"10.1093/eurheartjsupp/suae085","DOIUrl":"10.1093/eurheartjsupp/suae085","url":null,"abstract":"<p><p>This essay stems from a controversial recommendation present in the 2022 European Guidelines which indicated the appropriateness of considering an implantable cardioverter defibrillator (ICD) implant even for still asymptomatic long QT syndrome (LQTS) patients deemed to be at high risk by the 1-2-3 LQTS score based on QTc and genotype calculated prior to the institution of therapy. As 15 years ago, we also had proposed, but never used, a risk score called M-FACT to identify patients at high risk of an appropriate ICD shock, we felt the responsibility of assessing what would have happened to our patients if we had rigorously used that score. We performed a study recently published in the <i>European Heart Journal</i> which brought to general attention two concepts important for clinical management. One is that all LQTS patients should be seen at least once a year for a reassessment of arrhythmic risk based on standard electrocardiogram, 12-lead 24 h Holter recording and an exercise stress test. The other is that, based on these yearly visits, we perform 'therapy optimization' by adding to the standard β-blocker therapy either left cardiac sympathetic denervation or mexiletine or an ICD implant. On almost 1000 LQTS patients, all genotyped, this dynamic approach was accompanied by not a single death, few events, and out of 142 patients who should have received an ICD based on the score, only 22 did and only 3 had an ICD shock. These data and concepts call for a reconsideration of the recommendation made by the guidelines.</p>","PeriodicalId":11956,"journal":{"name":"European Heart Journal Supplements","volume":"27 Suppl 1","pages":"i47-i50"},"PeriodicalIF":1.7,"publicationDate":"2025-02-19","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11836685/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143467428","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
The role of functional assessment in the management of ischaemic heart disease.
IF 1.7 4区 医学 Q3 CARDIAC & CARDIOVASCULAR SYSTEMS Pub Date : 2025-02-19 eCollection Date: 2025-02-01 DOI: 10.1093/eurheartjsupp/suae121
Francesco Prati, Mario Albertucci, Flavio Giuseppe Biccire', Laura Gatto

Over the past three decades, ischaemia research has been the cornerstone of the management and treatment of patients with atherosclerotic CAD. A robust body of evidence, including non-randomized and randomized trials, has supported the use of invasive and non-invasive coronary function tests to guide coronary revascularization. However, more recent data have questioned the clinical benefits of adopting this approach, especially in patients admitted with acute myocardial infarction. The increasing use of intracoronary imaging has identified the morphological features of plaques at higher risk of causing subsequent acute coronary events, despite the fact that they were not obstructive at the time of the index investigation. However, although functional assessment does not appear to have the same potential for identifying high-risk plaques as imaging modalities, it offers the simplicity and reproducibility of plaque assessment as a unique advantage. Furthermore, the ideal approach for the treatment of the so-called vulnerable plaques is still far from being identified, while a robust body of evidence supports the role of functionally guided revascularization, especially in stable patients. Overall, ischaemia research still provides non-negligible information that contributes to a personalized approach to improve patient outcomes.

{"title":"The role of functional assessment in the management of ischaemic heart disease.","authors":"Francesco Prati, Mario Albertucci, Flavio Giuseppe Biccire', Laura Gatto","doi":"10.1093/eurheartjsupp/suae121","DOIUrl":"10.1093/eurheartjsupp/suae121","url":null,"abstract":"<p><p>Over the past three decades, ischaemia research has been the cornerstone of the management and treatment of patients with atherosclerotic CAD. A robust body of evidence, including non-randomized and randomized trials, has supported the use of invasive and non-invasive coronary function tests to guide coronary revascularization. However, more recent data have questioned the clinical benefits of adopting this approach, especially in patients admitted with acute myocardial infarction. The increasing use of intracoronary imaging has identified the morphological features of plaques at higher risk of causing subsequent acute coronary events, despite the fact that they were not obstructive at the time of the index investigation. However, although functional assessment does not appear to have the same potential for identifying high-risk plaques as imaging modalities, it offers the simplicity and reproducibility of plaque assessment as a unique advantage. Furthermore, the ideal approach for the treatment of the so-called vulnerable plaques is still far from being identified, while a robust body of evidence supports the role of functionally guided revascularization, especially in stable patients. Overall, ischaemia research still provides non-negligible information that contributes to a personalized approach to improve patient outcomes.</p>","PeriodicalId":11956,"journal":{"name":"European Heart Journal Supplements","volume":"27 Suppl 1","pages":"i27-i30"},"PeriodicalIF":1.7,"publicationDate":"2025-02-19","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11836690/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143467362","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
SGLT2 inhibitors and new frontiers in heart failure treatment regardless of ejection fraction and setting.
IF 1.7 4区 医学 Q3 CARDIAC & CARDIOVASCULAR SYSTEMS Pub Date : 2025-02-19 eCollection Date: 2025-02-01 DOI: 10.1093/eurheartjsupp/suae117
Anna Merlo, Emilia D'Elia, Luca Di Odoardo, Edoardo Sciatti, Michele Senni

Sodium-glucose cotransporter 2 inhibitors (SGLT2i) have been shown to reduce cardiovascular (CV) mortality and heart failure (HF) hospitalizations, independently from left ventricular ejection fraction (EF). Their efficacy has been assessed both in patients with reduced and preserved EF, with notable benefits in renal outcomes as well. The initiation of SGLT2i in the early phase of hospitalization for acute HF has proven to be safe and beneficial. The EMPULSE and DICTATE-AHF trials support early empagliflozin and dapagliflozin use, respectively, reducing worsening HF events, improving quality of life, and enhancing diuretic efficiency. Notably, these benefits emerge shortly after the initiation of therapy, underscoring the importance of early integration into guideline-directed medical therapy (GDMT). Despite concerns regarding deterioration of renal function, SGLT2i appear to be safe even in patients with low estimated glomerular filtration rates (eGFR). Data suggest that SGLT2i benefits persist without increased safety risks, reassuring clinicians of their efficacy in patients experiencing renal decline. Concerns about volume depletion induced by SGLT2i have also been addressed, with documented enhanced diuresis without adverse renal impacts. Moreover, SGLT2i have been associated with a lower risk of hyperkalaemia events, thus allowing for better optimization of GDMT, including the use of mineralocorticoid receptor antagonists. Overall, these findings highlight the broad CV, renal, and metabolic benefits of SGLT2i, advocating for their early and widespread use in HF management, regardless of EF or eGFR.

钠-葡萄糖共转运体 2 抑制剂(SGLT2i)已被证明可降低心血管(CV)死亡率和心力衰竭(HF)住院率,而与左心室射血分数(EF)无关。其疗效已在射血分数降低和射血分数保持不变的患者中进行了评估,并在肾脏预后方面取得了显著疗效。事实证明,在急性心房颤动住院的早期阶段开始使用 SGLT2i 既安全又有益。EMPULSE和DICTATE-AHF试验分别支持早期使用empagliflozin和dapagliflozin,以减少HF恶化事件、改善生活质量并提高利尿效率。值得注意的是,这些益处在开始治疗后不久就出现了,这凸显了尽早纳入指南指导的医疗疗法(GDMT)的重要性。尽管有人担心 SGLT2i 会导致肾功能恶化,但它似乎对估计肾小球滤过率(eGFR)较低的患者也是安全的。数据表明,SGLT2i 的疗效持续存在,且不会增加安全风险,这让临床医生对其在肾功能衰退患者中的疗效更加放心。人们对 SGLT2i 引起的容量耗竭的担忧也得到了解决,有记录显示,SGLT2i 可增强利尿作用,但不会对肾脏产生不良影响。此外,SGLT2i 与较低的高钾血症事件风险相关,因此可以更好地优化 GDMT,包括使用矿皮质激素受体拮抗剂。总之,这些研究结果凸显了 SGLT2i 在心血管、肾脏和代谢方面的广泛优势,主张在高血压治疗中尽早广泛使用 SGLT2i,无论 EF 或 eGFR 如何。
{"title":"SGLT2 inhibitors and new frontiers in heart failure treatment regardless of ejection fraction and setting.","authors":"Anna Merlo, Emilia D'Elia, Luca Di Odoardo, Edoardo Sciatti, Michele Senni","doi":"10.1093/eurheartjsupp/suae117","DOIUrl":"10.1093/eurheartjsupp/suae117","url":null,"abstract":"<p><p>Sodium-glucose cotransporter 2 inhibitors (SGLT2i) have been shown to reduce cardiovascular (CV) mortality and heart failure (HF) hospitalizations, independently from left ventricular ejection fraction (EF). Their efficacy has been assessed both in patients with reduced and preserved EF, with notable benefits in renal outcomes as well. The initiation of SGLT2i in the early phase of hospitalization for acute HF has proven to be safe and beneficial. The EMPULSE and DICTATE-AHF trials support early empagliflozin and dapagliflozin use, respectively, reducing worsening HF events, improving quality of life, and enhancing diuretic efficiency. Notably, these benefits emerge shortly after the initiation of therapy, underscoring the importance of early integration into guideline-directed medical therapy (GDMT). Despite concerns regarding deterioration of renal function, SGLT2i appear to be safe even in patients with low estimated glomerular filtration rates (eGFR). Data suggest that SGLT2i benefits persist without increased safety risks, reassuring clinicians of their efficacy in patients experiencing renal decline. Concerns about volume depletion induced by SGLT2i have also been addressed, with documented enhanced diuresis without adverse renal impacts. Moreover, SGLT2i have been associated with a lower risk of hyperkalaemia events, thus allowing for better optimization of GDMT, including the use of mineralocorticoid receptor antagonists. Overall, these findings highlight the broad CV, renal, and metabolic benefits of SGLT2i, advocating for their early and widespread use in HF management, regardless of EF or eGFR.</p>","PeriodicalId":11956,"journal":{"name":"European Heart Journal Supplements","volume":"27 Suppl 1","pages":"i137-i140"},"PeriodicalIF":1.7,"publicationDate":"2025-02-19","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11836731/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143467081","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Subclinical atrial fibrillation/atrial high-rate episodes: what significance and decision-making?
IF 1.7 4区 医学 Q3 CARDIAC & CARDIOVASCULAR SYSTEMS Pub Date : 2025-02-19 eCollection Date: 2025-02-01 DOI: 10.1093/eurheartjsupp/suae088
Giuseppe Boriani, Enrico Tartaglia, Paola Trapanese, Francesco Tritto, Luigi Gerra, Niccolò Bonini, Marco Vitolo, Jacopo F Imberti, Davide A Mei

Subclinical atrial fibrillation (AF) and atrial high-rate episodes (AHREs) are often detected incidentally through cardiac implantable electronic devices or wearables, especially in asymptomatic patients. These episodes pose a clinical challenge as they are associated with an increased risk of stroke, albeit at a lower rate compared with clinical AF. This review discusses the evolving understanding of AHRE, highlighting the uncertainties regarding optimal management, particularly the use of oral anticoagulants. Two key trials, ARTESiA and NOAH-AFNET 6, investigated anticoagulation in patients with device-detected AHRE. ARTESiA found that apixaban significantly reduced stroke or systemic embolism, but with an increased risk of major bleeding. In contrast, NOAH-AFNET 6, which tested edoxaban, did not demonstrate a significant benefit in reducing cardiovascular events but also observed higher bleeding rates. A meta-analysis of these trials confirmed the efficacy of oral anticoagulants in lowering ischaemic stroke risk, though with an elevated bleeding risk. Given these findings, clinical decision-making in patients with AHRE must be individualized, taking into account stroke risk, bleeding risk, and patient preferences. Shared decision-making is crucial to balance the benefits and risks of anticoagulation, especially in the context of progression to clinical AF and its associated stroke risk. Moreover, it is essential to educate patients about the risk of bleeding complications and emphasize the importance of close monitoring. Future research may further clarify optimal anticoagulation strategies and better define high-risk subgroups that would most benefit from therapy.

{"title":"Subclinical atrial fibrillation/atrial high-rate episodes: what significance and decision-making?","authors":"Giuseppe Boriani, Enrico Tartaglia, Paola Trapanese, Francesco Tritto, Luigi Gerra, Niccolò Bonini, Marco Vitolo, Jacopo F Imberti, Davide A Mei","doi":"10.1093/eurheartjsupp/suae088","DOIUrl":"10.1093/eurheartjsupp/suae088","url":null,"abstract":"<p><p>Subclinical atrial fibrillation (AF) and atrial high-rate episodes (AHREs) are often detected incidentally through cardiac implantable electronic devices or wearables, especially in asymptomatic patients. These episodes pose a clinical challenge as they are associated with an increased risk of stroke, albeit at a lower rate compared with clinical AF. This review discusses the evolving understanding of AHRE, highlighting the uncertainties regarding optimal management, particularly the use of oral anticoagulants. Two key trials, ARTESiA and NOAH-AFNET 6, investigated anticoagulation in patients with device-detected AHRE. ARTESiA found that apixaban significantly reduced stroke or systemic embolism, but with an increased risk of major bleeding. In contrast, NOAH-AFNET 6, which tested edoxaban, did not demonstrate a significant benefit in reducing cardiovascular events but also observed higher bleeding rates. A meta-analysis of these trials confirmed the efficacy of oral anticoagulants in lowering ischaemic stroke risk, though with an elevated bleeding risk. Given these findings, clinical decision-making in patients with AHRE must be individualized, taking into account stroke risk, bleeding risk, and patient preferences. Shared decision-making is crucial to balance the benefits and risks of anticoagulation, especially in the context of progression to clinical AF and its associated stroke risk. Moreover, it is essential to educate patients about the risk of bleeding complications and emphasize the importance of close monitoring. Future research may further clarify optimal anticoagulation strategies and better define high-risk subgroups that would most benefit from therapy.</p>","PeriodicalId":11956,"journal":{"name":"European Heart Journal Supplements","volume":"27 Suppl 1","pages":"i162-i166"},"PeriodicalIF":1.7,"publicationDate":"2025-02-19","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11836730/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143467083","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
期刊
European Heart Journal Supplements
全部 Acc. Chem. Res. ACS Applied Bio Materials ACS Appl. Electron. Mater. ACS Appl. Energy Mater. ACS Appl. Mater. Interfaces ACS Appl. Nano Mater. ACS Appl. Polym. Mater. ACS BIOMATER-SCI ENG ACS Catal. ACS Cent. Sci. ACS Chem. Biol. ACS Chemical Health & Safety ACS Chem. Neurosci. ACS Comb. Sci. ACS Earth Space Chem. ACS Energy Lett. ACS Infect. Dis. ACS Macro Lett. ACS Mater. Lett. ACS Med. Chem. Lett. ACS Nano ACS Omega ACS Photonics ACS Sens. ACS Sustainable Chem. Eng. ACS Synth. Biol. Anal. Chem. BIOCHEMISTRY-US Bioconjugate Chem. BIOMACROMOLECULES Chem. Res. Toxicol. Chem. Rev. Chem. Mater. CRYST GROWTH DES ENERG FUEL Environ. Sci. Technol. Environ. Sci. Technol. Lett. Eur. J. Inorg. Chem. IND ENG CHEM RES Inorg. Chem. J. Agric. Food. Chem. J. Chem. Eng. Data J. Chem. Educ. J. Chem. Inf. Model. J. Chem. Theory Comput. J. Med. Chem. J. Nat. Prod. J PROTEOME RES J. Am. Chem. Soc. LANGMUIR MACROMOLECULES Mol. Pharmaceutics Nano Lett. Org. Lett. ORG PROCESS RES DEV ORGANOMETALLICS J. Org. Chem. J. Phys. Chem. J. Phys. Chem. A J. Phys. Chem. B J. Phys. Chem. C J. Phys. Chem. Lett. Analyst Anal. Methods Biomater. Sci. Catal. Sci. Technol. Chem. Commun. Chem. Soc. Rev. CHEM EDUC RES PRACT CRYSTENGCOMM Dalton Trans. Energy Environ. Sci. ENVIRON SCI-NANO ENVIRON SCI-PROC IMP ENVIRON SCI-WAT RES Faraday Discuss. Food Funct. Green Chem. Inorg. Chem. Front. Integr. Biol. J. Anal. At. Spectrom. J. Mater. Chem. A J. Mater. Chem. B J. Mater. Chem. C Lab Chip Mater. Chem. Front. Mater. Horiz. MEDCHEMCOMM Metallomics Mol. Biosyst. Mol. Syst. Des. Eng. Nanoscale Nanoscale Horiz. Nat. Prod. Rep. New J. Chem. Org. Biomol. Chem. Org. Chem. Front. PHOTOCH PHOTOBIO SCI PCCP Polym. Chem.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
0
微信
客服QQ
Book学术公众号 扫码关注我们
反馈
×
意见反馈
请填写您的意见或建议
请填写您的手机或邮箱
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
Book学术官方微信
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术
文献互助 智能选刊 最新文献 互助须知 联系我们:info@booksci.cn
Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。
Copyright © 2023 Book学术 All rights reserved.
ghs 京公网安备 11010802042870号 京ICP备2023020795号-1